Developer of therapeutics for the treatment of cancer, rare diseases, and others. Its proprietary technology is the use of mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. It applies its technologies for the development of cancer therapies, antibody therapies, the treatment of rare diseases, and prophylactic vaccines. It has developed a synthetic biology-based, artificial intelligence-aided platform that helps to design b Founded in 2016, headquartered in Gaithersburg, United States. The company has raised $12.3M at the Series A stage backed by investors including TMCP, Sirnaomics, Rotating Boulder Fund, Shenzhen Hongtao Fund Management. Operating in Life Sciences > Oncology, Life Sciences > Infectious Diseases.
← All startups
mRNA
Series ADeveloper of therapeutics for the treatment of cancer, rare diseases, and others. Its proprietary technology is the use of mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. It applies its technologies for the development of cancer therapies, antibody therapies, the treatment of rare diseases, and prophylactic vaccines. It has developed a…
About
Business model
Oncology > Drugs > Diversified,
Infectious Diseases > Drugs > Diversified,
Rare Diseases > Drugs > Diversified,
Genomics > Applied Genomics > Synthetic Biology
Institutional investors
TMCPSirnaomicsRotating Boulder FundShenzhen Hongtao Fund Management
Latest coverage
📰 See all funding news — keep up with the raises that set comps.
Investor directory
🗂️ Explore Life Sciences investors — funds that write checks in this sector.